Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy.

Oliver Klein, Matteo S Carlino + Show 7 more

Open Access

PDF Available

https://doi.org/10.1016/j.ccell.2021.04.005

Copy DOI

Export

Save

Share

Cite

Journal: Cancer Cell	Publication Date: Apr 29, 2021
Citations: 45	License type: publisher-specific-oa

Affiliation: Olivia Newton-John Cancer Wellness & Research Centre, Austin Health, Blacktown & Mount Druitt Hospital, University of Sydney, La Trobe University, Albury Wodonga Health, Peter MacCallum Cancer Centre, Thermo Fisher Scientific (Israel), Alfred Health, Monash University

#Full Text PDF PubMed Scopus #Tumor Mutational Burden #Median Tumor Mutational Burden #Tumor Mutational Burden In Patients #Board Fees #Google Scholar #Cytotoxic T-lymphocyte-associated Protein 4 #Cytotoxic T-lymphocyte-associated Protein 4 Blockade #Combination Immunotherapy #Value Of Tumor Mutational Burden

Abstract
Full-Text PDF
Similar Papers

Abstract

Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy.

Full Text

Published Version (Free)

View/Download pdf

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Cancer Cell

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.